HCM
Hutchmed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
HCM Profile
Hutchmed (China) Limited
A developer of drugs for the treatment of oncology and immunological diseases for global market
Pharmaceutical
12/18/2000
03/17/2016
NASDAQ Stock Exchange
1,780
12-31
Depository Receipts (Ordinary Shares)
48th Floor, heung Kong Center, 2 Queen’s Road Central, Hong Kong
Hutchison Pharmaceuticals (China) Co., Ltd. (the 'Company ') and its subsidiaries (collectively the' Group ') are principally engaged in the research and development, production and marketing of pharmaceuticals. The Group has R&D facilities and production plants in the People's Republic of China (' China ') and sells its products mainly in China (including Hong Kong and Macau). In addition, the Group has established international operations in the United States and Europe.
Hutchison Pharmaceuticals (China) Co., Ltd. is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The company operates its business primarily through two divisions. The Tumor Immunology business segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases. R & D includes R&D activities covering drug discovery, development, production and regulatory functions. Listed products include the invoiced sales, promotion, production and distribution of drugs developed through R&D activities. Other business segments are engaged in other commercialization businesses, including the sales, promotion, production and distribution of other prescription drugs and health products.
